am 251 has been researched along with Fatty Liver, Nonalcoholic in 1 studies
AM 251: an analog of SR141716A; structure given in first source
AM-251 : A carbohydrazide obtained by formal condensation of the carboxy group of 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with the amino group of 1-aminopiperidine. An antagonist at the CB1 cannabinoid receptor.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, CC | 1 |
| Lee, TY | 1 |
| Kwok, CF | 1 |
| Hsu, YP | 1 |
| Shih, KC | 1 |
| Lin, YJ | 1 |
| Ho, LT | 1 |
1 other study available for am 251 and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Using proteomics to discover novel biomarkers for fatty liver development and response to CB1R antagonist treatment in an obese mouse model.
Topics: Animals; Biomarkers; Cannabinoid Receptor Antagonists; Diet, High-Fat; Male; Mice; Mice, Inbred C57B | 2017 |